Risk Factors for Aneurysm Rebleeding

Subarachnoid Hemorrhage, Aneurysmal Clinical Trial

Official title:

Risk Factors in Predicting Spontaneous Intracranial Aneurysm Rebleeding During Hospitalization

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01567449
• Other study ID #: 110011
• Status: Unknown status
• Phase: N/A
• First received: March 25, 2012
• Last updated: March 28, 2012
• Start date: September 2011
• Est. completion date: April 2012

Study information

• Verified date: March 2012
• Source: Fujian Medical University
• Contact: qingsong lin, master
• Phone: 13489991226
• Email: lqs1210305061[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to examine the risk factors for aneurysm rebleeding.

Description:

To investigate risk factors for spontaneous aneurysm rebleeding during hospitalization and to reach conclusions if any,of clinical signs for predicting rebleeding.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 66
• Est. completion date: April 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Individual whose clinical course was clear enough to be traced back and whose conservative treatment duration was shorter than 6 weeks was included

Exclusion Criteria:

• Rebleeding patients with certain inducing factors such as:

• severe emotional episode,

• severe coughing,

• constipation,

• excessive activities, or

• with coagulation disorder,or

• with other intracranial vascular malformations,such as:

• moyamoya disease,

• arteriovenous malformation were excluded.

• Also patients who rebled while angiography were excluded.

Related Conditions & MeSH terms

• Aneurysm
• Hemorrhage
• Subarachnoid Hemorrhage
• Subarachnoid Hemorrhage, Aneurysmal

Locations

Country	Name	City	State
China	First Affiliated Hospital,Fujian Medical University	Fuzhou	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Fujian Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Aneurysm rebleeding		up to 7 months